Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 30:13:1083285.
doi: 10.3389/fonc.2023.1083285. eCollection 2023.

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses

Jan M van Rees  1 , Lissa Wullaert  1 , Alexander A J Grüter  2 , Yassmina Derraze  2 , Pieter J Tanis  1 , Henk M W Verheul  3 , John W M Martens  3 , Saskia M Wilting  3 , Geraldine Vink  4   5 , Jeroen L A van Vugt  1 , Nick Beije  3 , Cornelis Verhoef  1
Affiliations

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses

Jan M van Rees et al. Front Oncol. .

Abstract

Background: Circulating tumour DNA (ctDNA) has been established as a promising (prognostic) biomarker with the potential to personalise treatment in cancer patients. The objective of this systematic review is to provide an overview of the current literature and the future perspectives of ctDNA in non-metastatic rectal cancer.

Methods: A comprehensive search for studies published prior to the 4th of October 2022 was conducted in Embase, Medline, Cochrane, Google scholar, and Web of Science. Only peer-reviewed original articles and ongoing clinical trials investigating the association between ctDNA and oncological outcomes in non-metastatic rectal cancer patients were included. Meta-analyses were performed to pool hazard ratios (HR) for recurrence-free survival (RFS).

Results: A total of 291 unique records were screened, of which 261 were original publications and 30 ongoing trials. Nineteen original publications were reviewed and discussed, of which seven provided sufficient data for meta-analyses on the association between the presence of post-treatment ctDNA and RFS. Results of the meta-analyses demonstrated that ctDNA analysis can be used to stratify patients into very high and low risk groups for recurrence, especially when detected after neoadjuvant treatment (HR for RFS: 9.3 [4.6 - 18.8]) and after surgery (HR for RFS: 15.5 [8.2 - 29.3]). Studies investigated different types of assays and used various techniques for the detection and quantification of ctDNA.

Conclusions: This literature overview and meta-analyses provide evidence for the strong association between ctDNA and recurrent disease. Future research should focus on the feasibility of ctDNA-guided treatment and follow-up strategies in rectal cancer. A blueprint for agreed-upon timing, preprocessing, and assay techniques is needed to empower adaptation of ctDNA into daily practice.

Keywords: Ctdna (circulating tumour DNA); cfDNA (circulating free DNA); liquid biopsy; minimal residual disease (MRD); rectal cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart.
Figure 2
Figure 2
Meta-analysis of the association between recurrence-free survival and the presence of ctDNA after neoadjuvant treatment (chemoradiation with or without systemic treatment).
Figure 3
Figure 3
Meta-analysis of the association between recurrence-free survival and the presence of ctDNA after curative intent surgery.
See this image and copyright information in PMC

References

    1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. . Cancer statistics for the year 2020: An overview. Int J Cancer (2021) 149(4):778–89. doi: 10.1002/ijc.33588 - DOI - PubMed
    1. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol (2011) 12(6):575–82. doi: 10.1016/S1470-2045(11)70097-3 - DOI - PubMed
    1. Badia-Ramentol J, Linares J, Gómez-Llonin A, Calon A. Minimal residual disease, metastasis and immunity. Biomolecules (2021) 11(2):130. doi: 10.3390/biom11020130 - DOI - PMC - PubMed
    1. Litvak A, Cercek A, Segal N, Reidy-Lagunes D, Stadler ZK, Yaeger RD, et al. . False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. J Natl Compr Canc Netw (2014) 12(6):907–13. doi: 10.6004/jnccn.2014.0085 - DOI - PMC - PubMed
    1. Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. . Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol (2019) 5(8):1124–31. doi: 10.1001/jamaoncol.2019.0528 - DOI - PMC - PubMed

Publication types

LinkOut - more resources